Van de Werf F, Brueckmann M, Connolly SJ, et al. A comparison of dabigatran etexilate with warfarin in patients with mechani- cal heart valves: the randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN). Am Heart J. 2012;163:931 7.e1. 4.2.2.2. Non-Vitamin K Oral Anticoagulants (Modified From Section 4.2.2.2. New Target-Specific Oral Anticoagulants in the 2014 AF Guideline) S4.2.2.2-1. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883 91. S4.2.2.2-2. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban ver- sus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093 104. S4.2.2.2-3. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran ver- sus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139 51. S4.2.2.2-4. Granger CB, Alexander JH, McMurray JJV, et al. Apixaban ver- sus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981 92. S4.2.2.2-5. Pan K-L, Singer DE, Ovbiagele B, et al. Effects of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and valvular heart disease: a systematic review and meta-analysis. J Am Heart Assoc. 2017;6:e005835. S4.2.2.2-6. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised tri- als. Lancet. 2014;383:955 62. S4.2.2.2-7. Abraham NS, Noseworthy PA, Yao X, et al. Gastrointestinal safety of direct oral anticoagulants: a large population-based study. Gastroenterology. 2017;152:1014 22.e1. S4.2.2.2-8. Graham DJ, Reichman ME, Wernecke M, et al. Stroke, bleeding, and mortality risks in elderly Medicare beneficiaries treated with dabigatran or rivaroxaban for nonvalvular atrial fibrillation. JAMA Intern Med. 2016;176:1662 71. S4.2.2.2-9. Larsen TB, Skj th F, Nielsen PB, et al. 